Apoptosis and Proliferation in Subcutaneous Panniculitis-Like T-Cell Lymphoma
Division of Pathology and Laboratory Medicine, University of Texas, MD Anderson Cancer Center, Houston 77030, USA. Modern Pathology
(Impact Factor: 6.19).
06/2002; 15(6):625-31. DOI: 10.1038/modpathol.3880577
Subcutaneous panniculitis-like T cell lymphoma (SPTCL), designated recently as a distinct clinicopathologic entity in the World Health Organization Classification, is a neoplasm composed of cytotoxic T-cells that preferentially involves subcutaneous adipose tissue. Histologically, SPTCL is characterized by extensive karyorrhectic debris and tumor necrosis suggesting that apoptotic mechanisms are involved in its pathogenesis. We assessed the apoptotic index (AI) and proliferation rate (PR) of 13 cases of SPTCL by TUNEL test and Ki-67 immunostaining, respectively. We also immunohistochemically assessed for expression of BCL-2 (anti-apoptosis), BAX (pro-apoptosis), and P53 and correlated the results with apoptosis and proliferation. We detected a high AI (median 8.1%) in 11 cases of SPTCL, and 12 cases had low BCL-2 and high BAX expression. BCL-2 expression inversely correlated with AI (P <.001) and BAX (P <.001). We found a low PR (cutoff > or = 25%) in eight (61%) cases. There was an inverse correlation between AI and PR (r = -.58, P =.04). Ten cases were assessed for P53; immunostaining results were heterogeneous but P53 expression correlated with large cell cytologic features. Our findings demonstrate that SPTCLs have a high AI that may be explained by differential expression of BCL-2 and BAX in the neoplastic cells.
Figures in this publication
Available from: nih.gov
[Show abstract] [Hide abstract]
ABSTRACT: To describe the current state of the knowledge regarding the pathology, clinical presentation, treatment strategies, and nursing management of patients with cutaneous T-cell lymphoma, specifically, mycosis fungoides and the Sezary syndrome.
Book chapters, review articles, published research studies, proceedings from professional meetings.
Although mycosis fungoides and the Sezary syndrome are rare, epidemiologic studies suggest an increasing incidence. Advances in cellular biology and immunology result in continuously changing diagnostic and treatment strategies aimed at this illness.
Oncology nurses need an understanding of the current state of the knowledge of cutaneous T-cell lymphoma to meet the extensive needs of patients confronted with this chronic, progressively devastating malignancy.
Seminars in Oncology Nursing 12/1998; 14(4):293-301. DOI:10.1016/S0749-2081(98)80007-7
Australian and New Zealand Journal of Obstetrics and Gynaecology 05/2003; 43(2):166-8. DOI:10.1046/j.0004-8666.2003.00035.x · 1.51 Impact Factor
Available from: L. Jeffrey Medeiros
[Show abstract] [Hide abstract]
ABSTRACT: Acute myeloid leukemia (AML) with inv(16)(p13q22), also known as M4Eo, is a distinct type of AML with a favorable prognosis associated with abnormal bone marrow eosinophils. We reviewed the morphologic findings of archival bone marrow specimens with M4Eo, specifically assessing for dysplasia, and performed immunohistochemical studies to assess the growth fraction using the MIB-1 (Ki-67) antibody. We also assessed the apoptotic rate by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labeling. All assessable cases had more than 10% dysplastic forms in at least 1 lineage. Seventeen cases had 10% or more dysplastic forms, and 3 cases had more than 50% dysplastic forms in at least 2 lineages. Immunoreactivity for Ki-67 was higher in M4Eo than in other AML types (P = .000). The apoptotic rate in M4Eo was similar to other AML types (P = .724). Our data show that dysplasia is a prominent feature, but not a prognostic indicator, in M4Eo. M4Eo is associated with a significantly higher proliferation rate than other AML types.
American Journal of Clinical Pathology 09/2003; 120(2):236-45. DOI:10.1309/PGNT-8LGN-9AR4-QVAJ · 2.51 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.